DekaBank Deutsche Girozentrale’s Kyverna Therapeutics KYTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,500	Closed	-$197K	–	1382
2025 Q4	$197K	Hold	7,500	–	–	﹤0.01%	1144
2025 Q3	$195K	Hold	7,500	–	–	﹤0.01%	1133
2025 Q2	$196K	Hold	7,500	–	–	﹤0.01%	1132
2025 Q1	$181K	Hold	7,500	–	–	﹤0.01%	1135
2024 Q4	$171K	Hold	7,500	–	–	﹤0.01%	1170
2024 Q3	$181K	Hold	7,500	–	–	﹤0.01%	1185
2024 Q2	$181K	Hold	7,500	–	–	﹤0.01%	1176
2024 Q1	$181K	Buy	+7,500	New	+$209K	﹤0.01%	1174

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

DekaBank Deutsche Girozentrale's KYTX Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Kyverna Therapeutics (KYTX) in Q1 2026, closing a stake of 7,500 shares — an estimated $197K sold.

DekaBank Deutsche Girozentrale first reported a position in KYTX in Q1 2024 and held it in 8 quarters. The position peaked at $197K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Kyverna Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 7,500 Kyverna Therapeutics shares in Q1 2026, an estimated $197K.
DekaBank Deutsche Girozentrale first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 8 quarters.
DekaBank Deutsche Girozentrale's Kyverna Therapeutics position peaked at $197K in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.